GL Pharm Tech Corporation   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Seongnam Korea, Republic of (2002)

Organization Overview

First Clinical Trial
2012
NCT01829893
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

GL PharmTech Corp. | GL Pharm Tech Corporation

Active Ingredients

Drugs in Phase 3 Trials (1)

tamsulosin (flomax) (3 trials)

Drugs in Phase 2 Trials (1)

glh8nde (2 trials)

Drugs in Phase 1 Trials (5)

finasteride (Proscar) (1 trial)

metformin (glucophage) (2 trials)

oxycodone (oxycontin) (2 trials)

pregabalin (lyrica) (7 trials)

sitagliptin (januvia) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 2)

Eye Diseases (Phase 2)

Hyperplasia (Phase 3)

Keratoconjunctivitis Sicca (Phase 2)

Malnutrition (Phase 1)

Neuralgia (Phase 1)

Prostatic Hyperplasia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 7